isoxazoles has been researched along with Thromboembolism in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Camu, F; Cheung, R; Joshi, GP; Pan, S; Schug, SA | 1 |
Bauleo, C; Catapano, G; Formichi, B; Genovesi, D; Giuntini, C; Mannucci, F; Marini, C; Michelassi, C; Monti, S; Prediletto, R | 1 |
Chonlahan, J; Halloran, MA; Hammonds, A | 1 |
2 review(s) available for isoxazoles and Thromboembolism
Article | Year |
---|---|
Cardiovascular safety of the cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: an analysis of integrated data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Female; Humans; Incidence; Isoxazoles; Male; Middle Aged; Pain, Postoperative; Postoperative Care; Risk Assessment; Risk Factors; Sulfonamides; Thromboembolism; Young Adult | 2009 |
Leflunomide and warfarin interaction: case report and review of the literature.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthritis, Rheumatoid; Atrial Fibrillation; Blood Coagulation; Drug Interactions; Female; Humans; International Normalized Ratio; Isoxazoles; Leflunomide; Middle Aged; Thromboembolism; Warfarin | 2006 |
1 other study(ies) available for isoxazoles and Thromboembolism
Article | Year |
---|---|
Improved survival in patients with inoperable chronic thromboembolic pulmonary hypertension.
Topics: Acid-Base Equilibrium; Aged; Antihypertensive Agents; Blood Gas Analysis; Bosentan; Cardiac Output; Chronic Disease; Drug Therapy, Combination; Exercise Test; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Oxygen Consumption; Oxygen Inhalation Therapy; Piperazines; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Thiophenes; Thromboembolism; Treatment Outcome; Vascular Resistance; Vasodilator Agents | 2013 |